Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results

Shares of Novo Nordisk, owner of Wegovy and Ozempic, fell sharply after its highly anticipated next-generation weight-loss drug, CagriSema, failed to meet investor expectations in testing, leading it to be branded 'obsolete'.

23 Feb, 14:26 — 23 Feb, 14:26

Post Share

Sources

Showing 1 of 1 sources

The GuardianMostly Factual48d ago

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations Business live – latest updates The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials. Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish firm’s CagriSema drug fell short of investors’ expectations. Continue reading...

By Julia Kollewe

Read full article →

PERSPECTA

PERSPECTA

Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results

Sources

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Related Stories

Zaanstad Attempts to Dismantle Criminal Window Cleaning Empire

Philippine President Marcos Urges Unity, Warns Against Hoarding Amid Energy Crisis

President Marcos Expected to Announce Decision on Fuel Excise Tax

Philippine President Marcos Jr. to Decide on Fuel Excise Tax by April 13

PERSPECTA